Stock WGS GENEDX HOLDINGS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings GeneDx Holdings Corp.

Equities

WGS

US81663L2007

Real-time Estimate Cboe BZX
Other stock markets
 12:27:50 2024-06-06 pm EDT 		5-day change 1st Jan Change
26.11 USD -4.29% Intraday chart for GeneDx Holdings Corp. +27.35% +844.23%
Jun. 05 GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients CI
Apr. 30 Health Care Flat Amid Mixed Earnings -- Health Care Roundup DJ

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
GENEDX HOLDINGS CORP. Stock GeneDx Holdings Corp.
+912.73% 713M -
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-22.94% 7.77B
B+
RADNET, INC. Stock RadNet, Inc.
+77.74% 4.51B
C+
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
+6.87% 2.76B
B-
SYNLAB AG Stock SYNLAB AG
-2.28% 2.67B -
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-47.96% 2.09B
B-
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-15.64% 1.72B
C-
FLEURY S.A. Stock Fleury S.A.
-19.96% 1.49B
A-
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+18.29% 1.22B
B+
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-44.77% 1.12B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. WGS Stock
  4. Ratings GeneDx Holdings Corp.